A retrospective study to evaluate efficacy and safety of oral tofacitinib in vitiligo and its variants

Vitiligo is a chronic autoimmune condition associatedwith marked psychological distress, especially in our country owing to thedarker skin types. There is a growing need for targeted therapies in vitiligofor its effective clearance. JAK (Janus kinase) inhibitors act by inhibitingIFN (Interferon) gamma signalling which is the main cytokine implicated in melanocytedestruction(1). However, data regarding ideal dosing, efficacy and long-term safety oforal tofacitinib in the Indian population is lacking. Through our study, wehope to bridge this gap and aid in creating a standardised protocol for the useof oral tofacitinib in vitiligo.